Skip to main content

Advertisement

Table 3 Clinical assessment and evaluation of the 74 dogs screened at the pre-inclusion visit

From: Six-month field efficacy and safety of the combined treatment of dogs with Frontline Tri-Act® and NexGard Spectra®

Leishmania infantum seropositive dogs 25/74 (33.8%)
Ehrlichia canis seropositive dogs 2/74 (2.7%)
Anaplasma spp. seropositive dogs 1/74 (1.4%)
Gastrointestinal parasite positive dogs 29/74 (39.2%)
Fleas positive dogs 26/74 (35.1%)
Ticks positive dogs 4/74 (5.4%)
Alterations of the haematological parameters 19/74 (25.7%)
Owners not complying with the study protocol 2/74 (2.7%)